Threemonthsafter the terminationof the trial, 61% of the study subjectstoldinvestigators that theybelievedalcohol was likelybeneficialand 49% were continuing todrink alcohol in moderation.
Novartis announced today the early terminationof the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at high risk for cardiovascular and renal events.